Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont


Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont

02-Jul-2020 / 13:59 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


 

 

Aubagne, France, July 2, 2020

 

Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont

 

Under the liquidity contract concluded between SARTORIUS STEDIM BIOTECH and the stockbroker Gilbert Dupont, the following assets appeared on the liquidity account on June 30, 2020:

 

  • Number of shares: 1,941
  • Liquidity account cash balance: €591,334.56

 

During the first half of 2020, the following were negotiated:

 

ORDER INTAKE

23,591 securities

4,975,493.75

972 transactions

SALES

24,875 securities

5,196,135.59

1,037 transactions

 

 

It should be noted that in the second half of 2019, which ended December 31, 2019, the following assets appeared on the liquidity account:

 

  • Number of shares: 3,225
  • Liquidity account cash balance: €370,692.66

 

It should also be noted that upon implementing the liquidity contract, the following assets were made available:

 

  • Number of shares: 654
  • Liquidity account cash balance: €394,895.12

 

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2019, the company employed approx. 6,200 people, and earned sales revenue of €1,440.6 million.

Contact

Ben Orzelek

Head of Investor Relations

+49 (0)551.308.1668

[email protected]

 

Sartorius Stedim Biotech S.A.

Z.I. Les Paluds

Avenue de Jouques, CS 91051

13781 Aubagne Cedex, France

Phone: +33.(0)4.42.84.56.00

Fax: +33.(0)4.42.84.56.19

www.sartorius-stedim.com

 

 


Regulatory filing PDF file

File: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont


Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: [email protected]
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext Ticker: DIM
AMF Category: Share buyback / Disposal of own shares / Information relating to the liquidity contract
EQS News ID: 1084849
 
End of Announcement EQS News Service

1084849  02-Jul-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1084849&application_name=news&site_id=sharewise

Sartorius Stedim Biotech S.A. Stock

€264.10
0.610%
Sartorius Stedim Biotech S.A. gained 0.610% compared to yesterday.

Like: 0
Share
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments